A

Anumana

www.anumana.ai link_icon

Anumana, Inc. - Company Market Research Report



Company Overview



  • Name: Anumana, Inc.

  • Mission: Anumana is dedicated to harnessing the electrical signals of the heart to diagnose and intervene in cardiac care earlier and more effectively through AI technology.

  • Founded: No information is available.

  • Founders: No information is available.

  • Key People:

  • Murali Aravamudan, Executive Chairman of the Board

  • Maulik Nanavaty, Chief Executive Officer

  • David McMullin, Chief Business Officer

  • Harry S. Palmin, Chief Financial Officer

  • Kyle Bettigole, SVP, General Counsel

  • Animesh Agarwal, Vice President of Product

  • Samir Awasthi, MD, PhD, Vice President of Clinical Research

  • Rakesh Barve, PhD, SVP of Data Science and Engineering

  • Suzanne Goodman, Vice President of Regulatory & Quality

  • Tyler Wagner, PhD, Vice President of Biomedical Research

  • Advisors:

  • Paul Friedman, MD from Mayo Clinic

  • Samuel J. Asirvatham, MD from Mayo Clinic

  • Zachi Attia, PhD from Mayo Clinic

  • Francisco Lopez-Jiminez, MD, MBA from Mayo Clinic

  • Rickey Carter, PhD from Mayo Clinic

  • Additional esteemed professionals from other notable institutions.

  • Headquarters: Cambridge, Massachusetts

  • Number of Employees: No information is available.

  • Revenue: No information is available.

  • What the Company is Known For: Anumana is recognized for its AI-driven technology solutions that improve cardiovascular care by offering early diagnoses and intervention capabilities.


Products



AI Medical Solutions


  • ECG-AI Platform:

  • High-Level Description: Uses advanced AI to analyze ECG data for early detection of cardiovascular diseases.

  • Key Features:

  • Algorithms trained on extensive ECG datasets.

  • FDA-cleared ECG-AI LEF for detecting low ejection fraction.


Electrocardiograhic and Electrophysiology Pipelines


  • Electrocardiography Pipeline:

  • Includes algorithms for detection of diseases such as pulmonary hypertension, cardiac amyloidosis, and hyperkalemia, some of which have received FDA Breakthrough Device Designation.


  • Electrophysiology Pipeline:

  • Targets improving procedure accuracy, safety, and outcomes in cardiac electrophysiology.


Software Solutions


  • Innovative Clinical Software:

  • Integrates AI solutions with existing clinical workflows, improving decision-making and patient care.

  • Integration Tools:

  • Designed to work with Electronic Health Records (EHR) and other point-of-care systems.


Recent Developments



  • New Products & Features:

  • Anumana's ECG-AI LEF received FDA clearance in 2023 for detecting low ejection fraction.

  • New AI algorithms for pulmonary hypertension and cardiac amyloidosis have received FDA Breakthrough Device Designation.


  • Partnerships:

  • Collaboration with InfoBionic.Ai to advance remote cardiac monitoring technologies.

  • Strategic alliance with Novartis to develop AI-driven diagnostic tools for heart diseases.

  • Awards:

  • The ECG-AI platform won the 2024 MedTech Breakthrough Award for best new technology in cardiology.


Conclusion



Anumana, Inc. is a leading AI health technology company focused on revolutionizing cardiac care through innovative AI solutions and strategic partnerships. By developing a robust portfolio of AI algorithms and tools, Anumana aims to transform the way cardiac diseases are detected and managed, providing critical benefits to patient outcomes and healthcare efficiency.